Breast cancer progression is likely a multistep process involving the activation and inactivation of a number of genes. Previously, we showed that the mRNA coding for Fra-1, a FOS family member and an AP-1 transcription factor component, was highly expressed in the more invasive estrogen receptor negative (ERÀ) breast cancer cell lines. We used a tet-off system to stably overexpress Fra-1 in MCF7 ER þ cells and evaluate the impact of Fra-1 on this aggressive phenotype. Conversely, Fra-1 was silenced in highly invasive ERÀMDA-MB231 cells using RNA interference. We report that in both systems the Fra-1 expression level was positively associated with cell proliferation, cell motility and invasiveness assessed in vitro. In addition, Fra-1 inhibition in fibroblastoid ERÀ cells, which formed colonies with large stellate projections in Matrigel, resulted in morphological changes. Cells acquired an epithelioid shape and had a spherical appearance in Matrigel. Fra-1 regulated several genes, implicated in invasion, angiogenesis and cell proliferation independently of b1-integrin activation, and directly induced MMP-1 and MMP-9 promoter activity. These overall results show that high Fra-1 expression is associated with a more malignant cell phenotype and suggest that Fra-1 could have a pivotal role in breast cancer progression.
Introduction
AP-1 activity is induced by a plethora of physiological stimuli such as growth factors and cytokines, and environmental stresses. In turn, AP-1 regulates a large variety of physiological processes including cell differentiation, proliferation, apoptosis and oncogenic transformation (Wisdom and Verma, 1993; Shaulian and Karin, 2002) . AP-1 transcription factors correspond to dimers of proteins encoded by Jun (c-Jun, JunB, JunD), Fos (c-Fos, Fra-1, Fra-2 and FosB), activating transcription factor (ATF2, LRF1/ATF3, B-ATF), Jun dimerization partner (JDP1 and JDP2) and Maf (c-Maf, MafA, MafB, MafG/F/K and Nrl) subfamilies (Chinenov and Kerppola, 2001) . ATF proteins form either homodimers or heterodimers with Jun proteins that preferentially bind to cAMP-responsive elements (Benbrook and Jones, 1990) . On the other hand, Jun homodimers or Jun-Fos heterodimers regulate gene transcription through interaction with a specific DNA sequence, that is, the 12-O tetra-decanoyl-phorbol-13 acetate (TPA) responsive element (TRE) (Angel et al., 1987) . Jun-Fos heterodimers are more stable than JunJun homodimers and therefore more efficient in transcription control. The combinatorial diversity of the dimers varies with the expression and activation level of the individual components according to cell types, environmental situations and different phases of the cell cycle, suggesting that dimers present different properties and functions (Chinenov and Kerppola, 2001 ).
Breast cancer is one of the leading causes of death in women. Breast cancer progression is likely a multistep process involving the activation or inactivation of a number of different genes. The majority of breast cancers express estrogen receptors (ERs) and the ER status of tumors helps to predict response to hormonal manipulation (McGuire, 1975) . In addition, ER þ tumors are histologically more differentiated and have a lower metastatic potential than ERÀ tumors (Fisher et al., 1981) . In multivariate analysis, ER status is an independent pronostic factor and the presence of functional ER is a marker of differentiation and a predictor of disease-free survival (Clark et al., 1984) .
Several human cell lines derived from breast cancers have been isolated. ER þ cells are not very metastatic in nude mice as compared to some ERÀ breast cancer cells (Thompson et al., 1992; Sommers et al., 1994) . Previously, we showed that binding to TRE, as measured by electrophoretic mobility shift assays, was drastically higher in cell extracts from ERÀ breast cancer cell lines than in ER þ breast cancer cell extracts. This differential binding resulted from the presence of a majority of AP-1 complexes containing Fra-1 in ERÀ cells. In fact, Fra-1 mRNA level was higher in the tested ERÀ cell lines than in ER þ cell lines, whereas no other obvious differences were detected with mRNA coding for other Fos family members or Jun proteins (Philips et al., 1998) . This result was further confirmed and extended by Zajchowski et al. (2001) who analysed, by cDNA array technology, 22 human mammary epithelial cell strains/lines (breast cancer cell lines and cells derived from primary or metastatic breast cancers and reduction mammoplasties). Among the 588 studied genes potentially important in human cancer, only Fra-1 and vimentin were found to be consistently associated with a highly aggressive phenotype.
In the present work, we assessed the role of Fra-1 in the aggressive phenotype of breast cancer cells. Two strategies were used: the first one was to overexpress Fra-1 in the MCF7 ER þ breast cancer cell line, the second was to inhibit Fra-1 expression in the MDA-MB231 ERÀ breast cancer cells. We show that the Fra-1 expression level influences cell proliferation, invasiveness and motility in vitro. In addition, Fra-1 accumulation is correlated with the expression of genes implicated in malignant progression. These results altogether suggest a pivotal role of Fra-1 in the progression of human breast cancers.
Results

Expression of Fra-1 in breast cancer cell lines
We (Philips et al., 1998) and others (Zajchowski et al., 2001) previously reported that a high Fra-1 mRNA concentration was present in some ERÀ breast cancer cell lines as compared to ER þ breast cancer cells. Fra-1 gene expression was analysed by Western blotting to confirm this result at the protein level (Figure 1 ). The Fra-1 signal varied strongly depending on the cell line. It was low in all the ER þ cell lines. In contrast, three ERÀ cell lines among four expressed a high Fra-1 level. Different forms of Fra-1 with apparent molecular weights ranging between 38 000 and 44 000 and corresponding to different degrees of phosphorylation (Gruda et al., 1994; Cook et al., 1999) were detected. In addition, a band migrating at 27 kDa was reproducibly present in MDA-MB436 cells. Interestingly, the three ERÀ cell lines which express a high Fra-1 expression level are those which display local invasiveness in nude mice and are the most active cells in chemoinvasion and chemotaxis assays, whereas SKBR3 cells are nontumorigenic in nude mice (Thompson et al., 1992; Sommers et al., 1994) .
Fra-1 overexpression in the MCF7 ER þ breast cancer cell line
To investigate whether Fra-1 takes part in the more aggressive phenotype of breast cancer cells, we first overexpressed Fra-1 under the tetracycline control in the MCF7 ER þ breast cancer cells (tet-off system). Human Fra-1 cDNA, cloned into an expression vector driven by a minimal cytomegalovirus promoter fused to the tet operator sequence, was stably transfected in an MCF7 clone (MCF7t) expressing tTA, a tetracycline-repressible transactivator, together with a hygromycin resistance plasmid. The results of Western blotting of lysates from hygromycin-resistant cells (MCF7-Fra-1) are shown in Figure 2a . Fra-1 content was greatly increased as compared to MCF7t control cells. It was efficiently inhibited by doxycycline, a tetracycline analogue, although a low basal level of Fra-1 was still detectable in most of the performed experiments. In the absence of doxycycline, the Fra-1 expression level in MCF7-Fra-1 cells was not very different from that observed in MDA-MB231 cells. However, the ratio between the fastest and slowest migrating bands appeared to be reversed in the two cell lines, showing that Fra-1 was most efficiently phosphorylated in the ERÀ cell line.
The inducible MCF7-Fra-1 cells were then analysed for their ability to form AP-1 complexes by electrophoretic mobility shift assays using a consensus TRE oligonucleotide. Sp1 DNA-binding activity was tested in parallel as a control of the efficiency of nuclear protein extraction in the different cell extracts. As shown in Figure 2b , higher protein binding to TRE was detected in MCF7-Fra-1 cells in the absence of doxycycline than in the presence of doxycycline or in the parental MCF7t cells. In addition, AP-1-mediated transcription, measured by transient transfection of reporter constructs containing four AP-1-binding sites, was increased by about threefold (Figure 2c ).
Inhibition of Fra-1 expression in the ERÀ MDA-MB231 cell line
Our second approach to study the function of Fra-1 involved specifically inhibiting Fra-1 expression in ERÀ breast cancer cells by RNA interference. The sense strand, the antisense strand and an siRNA duplex annealing to the green fluorescent protein (GFP) were used as controls. Lysates of MDA-MB231 cells transfected with these siRNA were tested in parallel by Western blotting for the expression of Fra-1, two other Fos family members (Fra-2 and c-Fos) and actin ( Figure 3A ). The Fra-1 signal level was decreased by more than 98% in cells transfected by Fra-1-specific siRNA compared to control. C-fos expression, which was not modulated by Fra-1 overexpression in MCF7 cells, was weakly but reproducibly reduced by Fra-1 siRNA. Actin and Fra-2 content was unaffected, thus Figure 1 Western blot analysis of Fra-1 expression in ER þ and ERÀ human breast cancer cell lines. Total proteins (90 mg) extracted from breast cancer cell lines were separated on SDS-PAGE and transferred to nitrocellulose membranes. Fra-1 protein was detected using specific anti-Fra-1 antibody Fra-1 in breast cancer cells K Belguise et al demonstrating the specificity of the silencing and the lack of general toxicity on the cells.
Fra-1 extinction in MDA-MB231 cells decreased binding to the AP-1-specific DNA sequence ( Figure 3B ) and led to a fivefold inhibition of AP-1-mediated transcription ( Figure 3C ). Moreover, Fra-1 siRNA rapidly changed the morphological appearance of the cells. While cells transfected with control siRNA displayed, like the nontransfected cell line, an elongated and fibroblastoid shape, Fra-1 siRNA-transfected cells exhibited a rounded and epithelioid morphology. In addition, Fra-1 siRNA induced a marked increase in the number of actin stress fibers and an enhancement in the size and number of focal adhesions, suggesting that cells are less motile than control cells ( Figure 3D ).
Effect of Fra-1 on breast cancer cell proliferation
We then investigated the effect of Fra-1 on cell proliferation. Overexpression of Fra-1 upon doxycycline removal did not significantly change the growth rate of MCF7-Fra-1 cells maintained in 10% serum (data not shown). However, when grown in medium with 1% serum, proliferation of Fra-1-overexpressing cells was enhanced as compared to the MCF7t parental cell line (Figure 4a ). This stimulation was almost totally abolished after doxycycline addition. The Fra-1 effect was detectable 4 days after plating and doxycycline removal and DNA content was enhanced by about twofold after 8 days.
Fra-1 siRNA efficiently decreased the Fra-1 concentration 48 h after transfection in MDA-MB231 cells ( Figure 3A ). This inhibition persisted in cells 9 days post-transfection (Figure 4b ), allowing us to study the MDA-MB231 cell growth after Fra-1 silencing ( Figure 4c ). Inhibition of Fra-1 had a drastic effect on cell proliferation. In cells maintained in 10% serum, DNA content was 4.5-fold decreased, 9 days after transfection with Fra-1-specific siRNA, as compared to control cells. Moreover, in the presence of 1% serum, Fra-1 inhibition resulted in almost growth arrest.
The effect of Fra-1 on cell cycle progression was then examined by FACS analyses of propidium iodide-stained nuclear DNA in both cellular systems maintained in 1% serum (Figure 4d ). Overexpression of Fra-1, in MCF7-Fra-1 cells, slightly decreased the fraction of cells in G0/G1 and increased the proportion of cells in S phase. Fra-1 extinction in MDA-MB231 cells resulted in dramatic reduction in the G0/G1 population. A drastic increase of the second peak was also observed. It should be noted that this peak may represent both G2/M-phase cells and cells arrested in G1 that contain a polyploid DNA content. In fact, labeling with DAPI revealed cells with bigger nuclei, as compared to control cells, in a proportion increasing with duration of Fra-1 silencing (not shown).
Effect of Fra-1 on outgrowth Matrigel assays
We then studied the growth of cell lines embedded in Matrigel, an artificial basement membrane. Published studies have correlated the stellate, invasive morphology of cancer cells in Matrigel with their metastatic potential (Thompson et al., 1992) . In fact, MCF7 cells had a smooth spherical appearance, whereas MDA-MB231 cells exhibited a stellate morphology with protrusions sprouting in the surrounding Matrigel when observed by phase contrast microscopy ( Figure 5 ). Overexpression of Fra-1 in MCF7 cells increased cell growth but did not change the colony phenotype ( Figure 5a ). By contrast, after inhibition of Fra-1 expression, MDA-MB231 cells formed well-delineated round colonies which resembled MCF7 cell colonies ( Figure 5b ). In addition, the cell colony number was greatly reduced by Fra-1 siRNA. 
Effect of Fra-1 in invasiveness and cell motility
We next analysed whether the Fra-1 expression level was correlated with the in vitro invasiveness of cells as tested by their capacity to pass through a Matrigel barrier in a modified Boyden chamber assay. The ability of MCF7-Fra-1 cells to invade through Matrigel was significantly enhanced 48 h after seeding, as compared to control cells cultivated in the presence of doxycycline or wild-type MCF7 cells (Figure 6a ). This change in invasion led us to examine the Fra-1 effect on cell migration, one component of the invasion process. Fra-1 overexpression increased cell motility by more than twofold, as measured by the same assay in the absence of Matrigel. We then tested whether inhibition of Fra-1 expression in MDA-MB231 cells was sufficient to decrease invasion and migration ( Figure 6b ). In vitro invasion and migration of cells transfected with Fra-1 siRNA was reduced by B3-and 2-fold, respectively, as compared to control cells. Once again, Fra-1 inhibition in MDA-MB231 cells had a more drastic effect than its overexpression in MCF7, since inhibition was observed as early as 24 h after cell seeding.
Fra-1 regulates the expression of proteins implicated in tumor progression
To search for genes whose regulation by Fra-1 might explain the more aggressive phenotype of Fra-1-overexpressing cells, MCF7-Fra-1 cells cultivated in the presence or absence of doxycycline for 48 h were analysed in DNA microarray experiments for the expression of 588 genes implicated in cell proliferation and invasion using Atlas Human Cancer membranes from Clontech (not shown). Five genes corresponding to mRNAs whose concentrations were most increased by Fra-1 (changes of at least twofold in two independent experiments) were then selected and studied at the protein level after overexpression or silencing of Fra-1 to confirm the regulation (Figure 7 ). Among these genes, four (MMP-9, MMP-1, VEGF and TIMP1) code for secreted proteins which were analysed in conditioned media from MCF7 and MDA-MB231 cells. All of them showed much higher expression in conditioned medium from ERÀ cells (MDA-MB231 cells transfected with control siRNA) than in ER þ cells (MCF7-Fra-1 maintained in the presence of doxycycline). Note that Figure 7a were performed with secretion media, corresponding to 10 5 and 10 6 cells for the ERÀ and the ER þ cell lines, respectively. Cyclin D1 (CD1) was detected in lysates of the same number of ERÀ and ER þ cells. Protein signals were all decreased in MDA-MB231 cells transfected with Fra-1 siRNA (Figure 7a) . Moreover, Fra-1 overexpression in MCF7 cells was sufficient to increase them. However, except for cyclin D1, expression levels obtained in MCF7 cells never reached those observed in MDA-MB231 cells. In the two cellular systems, regulation was more drastic for MMP-9, MMP-1 and VEGF than for TIMP1 and cyclin D1. Zymograph analysis demonstrated that the secreted MMP-9 was active since it efficiently digested gelatin ( Figure 7b ). However, all MMPs were not regulated since the activity of MMP-2 detected in the same gel was unchanged after modulation of the Fra-1 concentration.
Implication of b1-integrin and AP-1 transcription factors in the regulation of Fra-1 target genes
In colon cancer cells, Fra-1 silencing has been recently reported to switch b1-integrin to an active ligand-binding state leading to activation of a RhoA-ROCK pathway responsible for the increased cell-substratum adhesion and loss of in vitro invasiveness (Vial et al., 2003) . In agreement with these data, transfection of b1-integrinspecific siRNA, in MDA-MB231 cells where Fra-1 expression was inhibited, resulted in a lower, punctuated focal adhesion labeling (Figure 8a ). However, b1-integrin extinction had no effect on expression of the Fra-1 target genes cyclin D1, MMP-1, MMP-9 and VEGF (Figure 8b) .
We therefore investigated whether some of these genes were direct targets of Fra-1-containing AP-1 complexes by transient transfection experiments in MCF7 cells. The effect of Fra-1 overexpression was tested on reporter constructs containing MMP-1 and MMP-9 promoters, mutated or not on AP-1 sites, which have been demonstrated to be essential for induction by AP-1 complexes. Fra-1 overexpression increased the transcriptional activity of wild-type MMP-1 and MMP-9 constructs but not that of AP-1-mutated reporters (Figure 8c) . Moreover, cotransfection of TAM67, an expression vector coding for a dominant-negative c-Jun mutant, abolished the 
Discussion
Previous reports have underlined a crucial role of Fra-1 in the transformation of several cell types. Ectopic Fra-1 in Rat-1A fibroblast cells is sufficient to induce tumorigenicity (Bergers et al., 1995) and Fra-1 is a crucial mediator of the Ras-transformation process in NIH-3T3 cells (Mechta et al., 1997) . Establishment of the neoplastic phenotype in retrovirally transformed rat thyroid cells also requires fra-1 gene induction (Vallone et al., 1997) . In addition, Fra-1 appears to be critical in mesothelial cell transformation by exposure to asbestos fibers (Ramos-Nino et al., 2002) . Finally, ectopic Fra-1 was shown to induce morphological transformation and increase in vitro invasiveness of epithelioid mouse adenocarcinoma cells, thus suggesting a role of this Fra-1 in breast cancer cells K Belguise et al protein in epithelial tumor progression (Kustikova et al., 1998) . We and others shown that Fra-1 expression is associated with the aggressive behavior of breast cancer cell lines (Philips et al., 1998; Zajchowski et al., 2001) and is correlated with the absence of ER expression and a more undifferentiated phenotype in breast cancers (Bamberger et al., 1999 (Bamberger et al., , 2000 . However, the role of Fra-1 in breast cancer cells has not yet been addressed. Our purpose was therefore to determine whether the high Fra-1 concentration detected in some ERÀ breast cancer cell lines takes part in the aggressive phenotype of these cells. By increasing Fra-1 expression in ER þ MCF7 cells and silencing Fra-1 expression in ERÀ MDA-MB231 cells, we report that Fra-1 concentration was positively correlated with increased in vitro cell growth and invasiveness. In fact, overexpression of Fra-1 was sufficient to increase MCF7 cell proliferation and motility and, conversely, Fra-1 silencing was sufficient to decrease the two parameters in MDA-MB231 cells. We also found that some tumor progression-associated proteins, namely VEGF, MMP-1 and MMP-9, were highly regulated by Fra-1. Angiogenesis is necessary for the growth and invasiveness of primary tumors and involved in tumor metastasis (Fidler and Ellis, 1994; Gasparini, 2000) . The potent angiogenic factor VEGF is overexpressed in breast tumors as compared to surrounding normal tissue (Yoshiji et al., 1996a) and retrospective studies have shown its interest as a prognostic indicator of the severity of breast cancer (Gasparini, 2000) . In addition, a VEGF isoform has been shown to stimulate the invasion of T47D breast cancer cells in Matrigel (Price et al., 2001) . MMPs, Proteins were subjected to gelatin zymography as described in Materials and methods
Figure 8
Implication of b1-integrin and AP-1 complexes in the regulation of Fra-1 target genes. (a) Induction of focal adhesion by Fra-1 extinction is b1-integrin-dependent. MDA-MB231 cells were transfected with 400 nM Fra-1, b1-integrin and control siRNA alone or in combination for 2 days. Cells were immunostained with anti-phosphotyrosine antibodies (4G10) for focal adhesion labeling. (b) Regulation of cyclin D1, VEGF, MMP-1 and MMP-9 by Fra-1 inhibition is b1-integrin-independent. (a) Western blot analysis. Conditioned media and cellular extracts were prepared from MDA-MB231 cells, 48 h after transfection with Fra-1 and b1-integrin siRNAs alone or in combination and analysed by immunoblotting. For b1-integrin detection, cellular extracts were separated on nondenaturing SDS-PAGE. (c) MMP-1 and MMP-9 are direct transcriptional targets of AP-1. MCF7 cells were transfected with 1 mg of MMP-1 or MMP-9 promoter constructs containing a wild-type or mutated AP-1 site and 2 mg of CMVbgal. They were cotransfected with vectors encoding Fra-1 (0.5 mg) and the c-Jun dominant-negative mutant TAM67 (2 mg) when indicated. The results represent the mean (7s.d.) of luciferase activities calculated for triplicate wells from one experiment representative of three separate assays Fra-1 in breast cancer cells K Belguise et al which degrade extracellular matrix proteins, have long been associated with cancer cell invasion and metastasis and recent evidence suggests that some of them may also play a role in other steps of cancer development (for a review, see Egeblad and Werb, 2002) . MMP-1 has been described in a wide variety of cancers and in nearly all instances there was a significant correlation between the protein expression and survival (Brinckerhoff et al., 2000) . However, it has not yet been implicated in breast cancer aggressiveness contrary to MMP-9 whose downregulation was shown to reduce experimental metastasis in lung (Hua and Muschel, 1996) and whose overexpression stimulated cancer cell proliferation and reduced cancer cell apoptosis (Bergers et al., 2000; Coussens et al., 2000) . MMP-9 has also an important role in angiogenesis in transgenic models of tumor progression by increasing the bioavaibility of VEGF (Bergers et al., 2000; Coussens et al., 2000) . TIMP-1, an MMP inhibitor, which was also found to be regulated by Fra-1, was reported to be associated with bad prognosis in breast cancer (Yoshiji et al., 1998) , and its overexpression in rat mammary carcinoma enhances tumor growth and vascularization (Yoshiji et al., 1996b) . TIMP-1 (Hayakawa et al., 1992) and MMP-9 (Coussens et al., 2000) could also act on cell proliferation and TIMP-1 was shown to increase mammary cancer cell survival by inhibiting apoptosis (Li et al., 1999) . Severe growth retardation and embryonic lethality, due to a highly abnormal yolk sac and defect of vascularization of the placenta labyrinth layer, are observed in mice after inactivation of Fra-1 by gene targeting (Schreiber et al., 2000) . These observations are consistent with the induction of MMP-9 and VEGF by Fra-1. Indeed, MMP-9 plays an important role in the invasive processes involved in establishing foeto-maternal interaction (Birkedal-Hansen et al., 1993) and VEGF is crucial in vascularization during embryogenesis (Carmeliet et al., 1996) . Finally, overexpression of cyclin D1, another Fra-1 target, in mammary cells of transgenic mice results in abnormal cell proliferation, including the development of mammary carcinomas (Wang et al., 1994) . Data obtained by FACS analysis in cells where Fra-1 was silenced suggest that Cyclin D1, which controls progression through the G1 phase of the cell cycle (Baldin et al., 1993) , is probably not the only cell progression modulator regulated by Fra-1. However, inhibition of Fra-1 expression in ERÀ cells always had a more drastic effect than ectopic Fra-1 expression in ER þ cells. Whereas the Fra-1 level appeared to be equivalent in MCF7-Fra-1 and MDA-MB231 cells, Fra-1 overexpression only had an effect on cell proliferation in reduced serum concentrations, while Fra-1 inhibition had a drastic effect in all culture conditions. An approximately twofold decrease in cell invasion and motility was observed 24 h after Fra-1 inhibition, while ectopic Fra-1 expression required twofold more time to produce the opposite effect. In addition, while Fra-1 was efficient for stimulating MMP-9, MMP-1 and VEGF production in MCF7 cells, their induced expression was 10-fold lower than that measured in MDA-MB231 cells. Moreover, Fra-1 overexpression did not affect the morphology of MCF7 cells growing either on plastic or in Matrigel. These results altogether suggest that other factors, which were present at a higher concentration in ERÀ cells, are needed for Fra-1 action.
Such factors could be Fra-1 partners in AP-1 dimers. Differences in efficiency could also result from the phosphorylation state of Fra-1 itself. Phosphorylated Fra-1 was underrepresented in the ER þ cells, while the Fra-1 expression level in MDA-MB231 and MCF7-Fra-1 cells was comparable (Figure 2a) . Western blot data obtained with antibodies directed against ERK 1/2 indicated that the MAPK activation level was higher in MDA-MB231 cells than in MCF7 cells (not shown) in agreement with published observations (Krueger et al., 2001) . Interestingly, breast cancer cell motility is modulated by MAPK activation although increased activation of MAPK appears not sufficient to allow in vitro invasion in noninvasive MCF-7 cells (Krueger et al., 2001) . Fra-1 is a target for sustained activation of the MAPK cascade (Cook et al., 1999) . MAPK, which phosphorylates Fra-1 (Gruda et al., 1994; Cook et al., 1999; Hurd et al., 2002; Young et al., 2002) , increases fra-1 gene transcription (Hurd et al., 2002) but also Fra-1 DNA-binding activity (Gruda et al., 1994) and may affect Fra-1 transcriptional activity (Young et al., 2002) .
The role of Fra-1 in AP-1-dependent responses is still unclear. Fra-1 was found to inhibit TRE-mediated transcription induced by c-Jun and by c-Jun/c-Fos in mouse embryonic F9 cells and by TPA in HeLa cells (Suzuki et al., 1991; Yoshioka et al., 1995) , while increasing transcription in the presence of JunD. In fact, fusion to a heterologous DNA-binding domain has shown that Fra-1 lacks a transcriptional transactivation domain (Bergers et al., 1995) . It has therefore been proposed that Fra-1 activity could only result from its ability to form stable AP-1 heterodimers (Vallone et al., 1997) . Alternatively, the transactivation domain of Fra-1 might require activation by mitogenic factors or other stimuli. Young et al. (2002) indeed suggest that ERK 1/ 2-dependent activation of Fra-1 could be needed for the induction of AP-1-regulated responses. Moreover, although Fra-1 was a weak inductor of TRE-containing reporter constructs, it efficiently induced expression of some AP-1-responsive genes (Kustikova et al., 1998; Ozanne et al., 2000; Andersen et al., 2002) . Some of the AP-1-regulated genes that we had tested (MMP-1, MMP-9, VEGF) were highly dependent on Fra-1 expression, while others (TIMP1, cyclin D1) responded to a lesser extent or did not show any regulation (MMP-2, vimentin) (Figure 7 and unpublished data).
Some effects of Fra-1 might be not directly linked to its transcription potential (Andersen et al., 2002) . Vial et al. (2003) propose that Fra-1 could promote cell motility by inactivating b1-integrin and keeping RhoA activity low. In agreement with their results, obtained in colon cancer cells, b1-integrin silencing partly reverted the effect of Fra-1 siRNA on focal adhesions in MDA-MB231 breast cancer cells. However, in the same experimental conditions, it did not affect regulation of MMP-1, MMP-9, VEGF and cyclin D1, and both Fra-1 in breast cancer cells K Belguise et al metalloproteases were strongly suggested to be direct targets of Fra-1-containing AP-1 complexes. The fact that all AP-1-regulated genes were not regulated by Fra-1 could reflect an activation specificity of Jun-Fos dimers depending on the Fos partner and the target gene. In fact, specific AP-1 monomers joined via a flexible polypeptide to force specific pairing differ in their DNA-binding activity and transcriptional activation from different promoters (Bakiri et al., 2002) . Moreover, c-Fos and Fra-1, but not Fra-2, have been shown to activate genes of the urokinase system in murine epithelioid adenocarcinoma cells (Andersen et al., 2002) .
C-Jun overexpression was reported to produce a tumorigenic, invasive and hormone-resistant phenotype in MCF7 cells. These effects were associated with increased Fra-1 expression and loss of detectable ER (Smith et al., 1999) . We therefore tested the possibility that Fra-1, whose high expression level was only found in ERÀ breast cancer cell lines, was implicated in regulation of ER expression. We did not detect any change of ER concentration in MCF7-Fra-1 cells even after 2 months of culture (N Kersual, unpublished results).
In conclusion, we have shown that Fra-1, whose expression level is correlated with the expression of genes that have been implicated in cancer, influences cell proliferation, in vitro cell invasiveness and motility of breast cancer cells. These results altogether suggest that Fra-1 could have a pivotal role in breast cancer progression and could explain in part the efficacy of a DNA vaccine against Fra-1 in protecting against growth and metastases of breast cancer in a mouse model system (Luo et al., 2003) . Further clinical studies are, however, required to determine the prognostic and/or predictive value of Fra-1 in human breast cancer.
Materials and methods
Plasmids and siRNA
Reporter plasmid (AP-1)4-TK-CAT (Philips et al., 1993) and expression vectors pCI-Fra-1 (Philips et al., 1998) and TAM67 (Brown et al., 1996) have been described previously. To generate pUHC13.3/Fra-1, the pSKII-Fra-1 plasmid (Matsui et al., 1990) was digested with BamHI and ClaI and the Fra-1 cDNA insert was exchanged with the corresponding fragment of the pUHC13.3 vector (Gossen and Bujard, 1992) . MMP-1 constructs, which contain 4372 bp of the MMP-1 promoter with either wild-type or mutated AP-1 site at À73, are a gift of CE Brinckerhoff (Hanover, New Hampshire). MMP-9 constructs contain the sequence À670/ þ 54 of the MMP-9 promoter mutated or not on the AP-1 site at À73 and were donated by DD Boyd (Houston, TX, USA). The siRNA sequences targeting Fra-1 corresponded to the 124-144 coding region relative to the first nucleotide of the start codon. GFP-specific siRNA (Yu et al., 2002) , estrogen receptor-specific siRNA or the negative control 1 siRNA from Ambion (Humington, UK) were transfected in control cells when indicated.
Cell culture
MDA-MB231 and MCF7 cells were maintained in Dulbecco's modified Eagle medium/Ham's F-12 (1/1) supplemented with 10% fetal calf serum (FCS) and 50 mg/ml gentamycin. To generate stable cell lines which express Fra-1 in a tetracyclinecontrolled expression system, MCF7 cells were first transfected with the pUHD15-1 neo plasmid (Shan and Lee, 1994) which encodes tTA, a tetracycline-repressible transactivator, and contains a G418 resistance gene. The selected G418-resistant clone, MCF7t, was then cotransfected with pUHC13.3-Fra-1 and pY3, a hygromycin resistance plasmid. Hygromycinresistant cells were isolated and maintained in the presence of G418 (200 mg/ml) and hygromycin B (20 mg/ml). Doxycycline, a tetracycline analogue, was used at 10 À2 mg/ml when indicated.
Transient transfection and CAT and luciferase assays
Cells were transfected for 16 h using the calcium phosphate DNA co-precipitation method (Philips et al., 1993) . The bgalactosidase expression plasmid pCMVb (Clontech Laboratories, Palo Alto, CA, USA) was used for internal control of transfection efficiency. At 36 h after transfection, CAT assays were performed after normalization for b-galactosidase activity. Acetylated and nonacetylated forms of [ 14 C]chloramphenicol were separated by thin-layer chromatography. Quantification was performed with a Fuji BAS1000 Bioimaging Analyser (Raytest, Paris, France). Luciferase activity was measured using an LKB luminometer (LKB Instruments, Rockville, MD, USA).
siRNA transfection
At 24 h before transfection, 4 Â 10 5 cells were plated in 35-mm diameter wells. Transfections of siRNA duplex (1.3 mg per well, 200 nM final) were carried out using Oligofectamine, in Optimem serum-free medium (Invitrogen, Cergy Pontoise, France), following the manufacturer's instructions. Lipofectamine (Invitrogen) was used when siRNAs were cotransfected with reporter plasmids.
Gel retardation assay
Nuclear extracts were prepared as described by Stein et al. (1989) . Gel retardation assays were performed as described previously (Philips et al., 1998) . The oligonucleotide sequences were as follows: AP-1 DNA-binding site, 5
0 -CTAGCTGTCTG AGTCATGCA-3 0 and 5 0 -AGCTTGCATGACTCAGACAG-3 0 ; consensus Sp1 DNA-binding site, 5
0 -TCGATCGGGGCGGG GCGA-3 0 and 5 0 -GCTCGCCCCGCCCCGAT-3 0 .
Immunofluorescence
Cells were plated on glass coverslips, fixed with 3.7% paraformaldehyde/PBS solution, and permeabilized with 0.1% Triton X-100 in PBS. For actin cytoskeleton staining, coverslips were incubated with 25 ng/ml of TRITC-coupled phalloidin for 30 min. For focal adhesion staining, coverlips were incubated with 4G10 antibodies (Tang et al., 1995) for 1 h and after intermediate washes in 50 mM Tris (pH 7.5), 130 mM NaCl, 0.008% Triton X-100, incubated with FITC-conjugated anti-mouse IgG. After incubation with antibodies, nuclei were labeled with DAPI (1 mg/ml) for 1 min. Cells were examined with a Leica DMP A microscope and images were recorded with a cooled CCD Photometrics camera (Becton Dickinson).
Cell proliferation analysis
MCF7 cells were plated in 24-well plates at a density of 5 Â 10 3 cells/well in medium containing 5% FCS in the presence or absence of doxycycline. After 2 days, serum concentration was lowered to 1%. MDA-MB231 cells were plated in 12-well Fra-1 in breast cancer cells K Belguise et al plates (2 Â 10 4 cells/well) in medium containing 10% FCS. At 24 h after plating, cells were transfected with control or Fra-1 siRNA duplex. For cell proliferation in low serum conditions, 1 day later cells were incubated, for 2 days, in medium containing 5% FCS, and then, for 7 days, in medium containing 1% FCS. Growth was evaluated by total DNA measurement by the diaminobenzoic acid fluorimetric assay after in situ fixation with methanol (Chalbos et al., 1982) .
Flow cytometry analysis
MDA-MB231 cells were plated, at a density of 10 4 cells/cm À2 , in medium containing 10% FCS and transfected with control or Fra-1 siRNA 24 h after plating. After 1 day, media were changed and serum concentration was lowered to 5% for 24 h, then to 1% for 3 days. MCF7 cells were plated, at a density of 3 Â 10 4 cells/cm À2 in medium containing 5% FCS and in the presence or absence of doxycycline. After 1 day, serum concentration was lowered to 1% and cultures maintained for 4 days. Cells were then collected, washed with PBS and fixed with 75% ethanol for 2 min. They were incubated in PBS containing 40 mg/ml propidium iodide and 100 mg/ml RNAse A. After 30 min incubation at 371C, cell cycle was analysed with a FACScan flow cytometer and CellQuest software (Beckton Dickinson, Montain View, CA, USA).
Matrigel outgrowth assay
An 2 Â 10 4 subconfluent cells were harvested and re-suspended at 41C in Matrigel (0.2 ml, 6.3 mg/ml) (Becton Dickinson, Le Pont de Claix, France), an extracellular matrix extracted from Engelbreth-Holm-Swarm mouse tumor, and added to a pre-set Matrigel layer in 24-well plates as described (Thompson et al., 1992) . The top Matrigel cell layers were covered with culture medium containing 5% FCS.
Invasion and migration assays
A suspension of 9 Â 10 5 MCF7 cells was layered in the upper compartment of a Transwell (Costar, Cambridge, MA, USA) on a 12-mm diameter polycarbonate filter (12 mm pore size), and incubated for 24 or 48 h at 371C with 50 mg/ml fibronectin (Becton Dickinson) as attractant in the lower compartment. For MDA-MB231 cells, which are smaller than MCF7 cells, polycarbonate filters with a 8 mm pore size were used. At 48 h after transfection with siRNA duplex, a suspension of 3 Â 10 5 cells was layered in the upper compartment of a Transwell (6.5-mm diameter) and incubated for 24 h at 371C with 30 mg/ ml fibronectin in the lower compartment. For invasion assays, 6.5-or 12-mm diameter filters were precoated with 30 or 60 mg of Matrigel, respectively. Migration of the cells to the lower side of the filter was evaluated with the mitochondrial deshydrogenase enzymatic assay using 3(4,5-dimethyl-thiazol-2-yl) 2,5-diphenol tetrazolium bromide (MTT) and OD 540 nm determination.
Zymogram analyses
Cells, grown to 80% confluence, were incubated for 24 h in serum-free medium. Concentrated conditioned media, corresponding to the same number of cells in culture, were applied to nondenaturing 10% SDS-PAGE containing gelatin (1 mg/ ml). After electrophoresis, gels were washed for 1 h at room temperature in 50 mM Tris-HCl (pH 7.5) containing 2.5% Triton X-100 to remove SDS. They were then incubated at 371C, in 50 mM Tris-HCl (pH 7.5) containing 5 mM CaCl 2 and 1 mM ZnCl 2 , and stained with 0.2% Coomassie blue G-250.
Cell extracts and Western blotting
Cells were lysed at 41C in lysis buffer: 10 mM EDTA, 5 mM MgCl 2 , 100 mM sodium vanadate, 1% Triton X-100, 40 mM NaPPI, 50 mM NaF, 40 mM Tris (pH 8) and a cocktail of protease inhibitors. Cell extracts or conditioned media, collected as described for Zymogram analyses, were separated on SDS-PAGE, transferred to nitrocellulose membranes and probed with antibodies. Anti-human Fra-1 (R-20) and b1-integrin (P5D2) were purchased from Santa Cruz (Santa Cruz, CA, USA). Anti-human vascular endothelial growth factor (VEGF) and actin were from Sigma-Aldrich (L'Isle d'Abeau Chesnes, France), anti-human matrix metalloproteinases-9 (MMP-9) and -1 (MMP-1) from R&D System (Minneapolis, MN, USA), anti-cyclin D1 from BD PharMingen (San Diego, CA, USA) and antitissue inhibitor of metalloprotease-1 (TIMP-1) from Oncogene (Cambridge, MA, USA). After washing, peroxidase-conjugated anti-rabbit or anti-mouse IgG secondary antibodies were incubated with the membranes, washed and detected with Chemiluminescence Reagent Plus (Perkin-Elmer Life Sciences, Courtaboeuf, France).
